ChinaDaily Briefs

Daily Brief China: Laopu Gold, CK Hutchison Holdings, Smart Share Global, Meituan, Guangzhou Innogen Pharmaceutical Group and more

In today’s briefing:

  • Laopu Gold (6181 HK): Potential Inclusion in Both Global Indices
  • Weekly Deals Digest (03 Aug) – CK Hutchison, Joy City, HKBN, Fujitec, Krosaki Harima, NSDL
  • Smart Share Global (EM US): Trustar Capital-Sponsored MBO a Done Deal
  • Smart Share Global (EM US): MBO Firmed
  • ECM Weekly (4 August 2025)-Meituan, LG CNS, Wuxi AppTec, SICC, NSDL, Aditya Info, GigaDevice, WeWork
  • Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts


Laopu Gold (6181 HK): Potential Inclusion in Both Global Indices

By Brian Freitas

  • Laopu Gold (6181 HK) missed global index inclusion in May following completion of full circulation. The primary placement in May then improved chances of index inclusion in August.
  • The stock rose nearly 60% in the 2 months following the placement and has lost more than a third of its value from the peak in the last month.
  • The stock could be added to both global indices with one inclusion at the end of August and one in mid-September. That could provide short-term support for the stock.

Weekly Deals Digest (03 Aug) – CK Hutchison, Joy City, HKBN, Fujitec, Krosaki Harima, NSDL

By Arun George


Smart Share Global (EM US): Trustar Capital-Sponsored MBO a Done Deal

By Arun George

  • Smart Share Global (EM US) has entered into a definitive merger agreement for a Trustar Capital-sponsored MBO at US$1.25 per ADS. 
  • The proposal is conditional on regulatory approvals (low risk), shareholder approval (effectively done) and a maximum dissenting condition (likely to be waived).
  • This is a done deal. At the last close and for the end of December payment, the gross/annualised spread is 7.8%/20.1% (3.5%/8.7% including an ADS cancellation fee).  

Smart Share Global (EM US): MBO Firmed

By David Blennerhassett

  • Nearly seven months after Smart Share (EM US), the largest provider of mobile device charging services in China, announced a preliminary non-binding proposal, a firm Offer has been entered into.
  • Terms remains the same as the indicative NBIO: US$0.625/share (US$1.25/ADS), a 74.8% premium to last close. The Offeror comprises a consortium led by Mars Guangyuan Cai, Chairman and CEO.
  • Timing from here? Perhaps three to four months, or late November completion by my estimate. 

ECM Weekly (4 August 2025)-Meituan, LG CNS, Wuxi AppTec, SICC, NSDL, Aditya Info, GigaDevice, WeWork

By Sumeet Singh

  • Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
  • On the IPO front, India deal flow remains strong, with HK A/H listing starting to flow in again.
  • On the placements front, WuXi AppTec (2359 HK) undertook a mega raising, while Prosus NV (PRX NA) has begun to pare its stake in Meituan (3690 HK)

Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts

By Ke Yan, CFA, FRM

  • Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.
  • In this note, we look at changes to the company’s PHIP prospectus.
  • While there is no major update to the asset lists, we do see that the market forecasts provided in the prospectus scaled down significantly.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars